Literature DB >> 9685226

Differential regulation of the parathyroid hormone-related protein gene P1 and P3 promoters by cAMP.

P J Chilco1, V Leopold, J D Zajac.   

Abstract

The role of calcitonin, and other agonists which activate the cAMP pathway, in regulating transcription of the human parathyroid hormone-related protein (PTHrP) gene was investigated in a human lung cancer cell line (BEN). Both calcitonin and forskolin caused a 5-6-fold increase in transcription initiated from both the P1 and P3 promoters, but with no observed effect on the P2 promoter. Maximal 6-fold activation of the P1 promoter occurred at 16 h post-stimulation and effects of calcitonin were observed within the pM range. The PKC agonist, phorbol 12-myristate 13-acetate diester (PMA), did not modulate transcription initiated from the P1 promoter. The ionophore ionomycin had a small effect on transcription of the P1 promoter, and transcriptional control may involve an interaction between the cAMP and intracellular calcium second messenger pathways. Deletion mapping studies indicated that increases in transcription of the human PTHrP gene is being mediated via a CRE element situated at -3313 to -3306 upstream of the P1 promoter. Mutational analysis of this CRE element confirmed a role for this sequence in mediating the increase in transcription effected by cAMP. Consistent with these transfection studies, RT-PCR of PTHrP mRNA also indicated a significant increase in transcripts generated from the P1 promoter. Gel retardation assays utilising a fragment of the P1 promoter region, encompassing the putative CRE, determined that nuclear proteins were binding to this region. Competition binding studies with labelled probe and cold competitors determined that the binding was specific for this sequence. A wild-type CRE consensus oligonucleotide also competed for binding with this sequence.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9685226     DOI: 10.1016/s0303-7207(97)00239-6

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  8 in total

Review 1.  PTHrP gene expression in cancer: do all paths lead to Ets?

Authors:  Virgile Richard; Thomas J Rosol; John Foley
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2005       Impact factor: 1.807

2.  E1A oncogene expression inhibits PTHrP P3 promoter activity and sensitizes human prostate cancer cells to TNF-induced apoptosis.

Authors:  Farrokh K Asadi; Subhash C Kukreja; Brigitte Boyer; Ana-Maria Valess; James L Cook
Journal:  Int Urol Nephrol       Date:  2010-01-16       Impact factor: 2.370

3.  Switching of G-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells.

Authors:  Ramanaiah Mamillapalli; Joshua VanHouten; Walter Zawalich; John Wysolmerski
Journal:  J Biol Chem       Date:  2008-07-11       Impact factor: 5.157

4.  The calcium-sensing receptor couples to Galpha(s) and regulates PTHrP and ACTH secretion in pituitary cells.

Authors:  Ramanaiah Mamillapalli; John Wysolmerski
Journal:  J Endocrinol       Date:  2009-12-23       Impact factor: 4.286

5.  Cinacalcet for hypercalcemia caused by pulmonary squamous cell carcinoma producing parathyroid hormone-related Peptide.

Authors:  Anneke Bech; Koen Smolders; Darryl Telting; Hans de Boer
Journal:  Case Rep Oncol       Date:  2012-01-07

Review 6.  Calcium-Sensing Receptor in Breast Physiology and Cancer.

Authors:  Wonnam Kim; John J Wysolmerski
Journal:  Front Physiol       Date:  2016-09-30       Impact factor: 4.566

Review 7.  Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy.

Authors:  Jeremy S Frieling; Conor C Lynch
Journal:  Int J Mol Sci       Date:  2019-06-08       Impact factor: 5.923

8.  Hydrostatic pressure-dependent changes in cyclic AMP signaling in optic nerve head astrocytes from Caucasian and African American donors.

Authors:  Lin Chen; Thomas J Lukas; M Rosario Hernandez
Journal:  Mol Vis       Date:  2009-08-20       Impact factor: 2.367

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.